Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline.

Vividion Therapeutics一家临床阶段的生物制药公司，同时也是拜耳股份公司全资拥有并独立运营的子公司，今日宣布已获得临床阶段的维尔纳解旋酶（WRN）共价抑制剂VVD-214（RO7589831）的全球独家开发和商业化权利，进一步增强并补充了其创新肿瘤学开发管线。

VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020. Vividon utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders..

VVD-214 是 Vividion 和罗氏于 2020 年启动的独家全球合作和许可协议下发现和开发的。Vividion 利用创新的发现技术，解锁具有强烈疾病关联的难以成药的靶点，并针对毁灭性癌症和免疫疾病开发小分子精准治疗药物。

Preliminary data from a first-in-human study presented at the recent American Association for Cancer Research (AACR) Annual Meeting showed that VVD-214 is well tolerated and has promising signs of activity. Vividion will continue the clinical development of VVD-214 within the company’s pipeline of innovative investigational therapeutics for cancers and immune disorders..

最近在美国癌症研究协会（AACR）年会上公布的一项首次人体研究的初步数据显示，VVD-214耐受性良好，并显示出令人鼓舞的活性迹象。Vividion将继续在公司用于癌症和免疫疾病的创新研究性治疗药物管线中推进VVD-214的临床开发。

WRN is a DNA repair enzyme and a highly sought-after synthetic lethal target for treatment of cancers with microsatellite instability (MSI). By inhibiting WRN, VVD-214 aims to cause lethal DNA damage in cancers with high microsatellite instability while minimizing harm to healthy cells.

WRN是一种DNA修复酶，也是治疗微卫星不稳定性（MSI）癌症备受关注的合成致死靶点。通过抑制WRN，VVD-214旨在对高微卫星不稳定性癌症造成致死性DNA损伤，同时尽量减少对健康细胞的伤害。

“Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “We are eager to progress development of this compound, building on the encouraging clinical data we’ve seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.”.

“将全球唯一处于临床阶段的WRN共价抑制剂VVD-214纳入我们的产品组合，对Vividion来说是一个令人无比激动的时刻，”Vividion首席执行官Aleksandra Rizo医学博士表示。“我们渴望推进这一化合物的开发，基于迄今为止所见的鼓舞人心的临床数据，践行我们为癌症和其他严重疾病患者变革治疗的使命。”

The Phase I clinical trial (

第一阶段临床试验 (

NCT06004245

NCT06004245

) is evaluating VVD-214 as a monotherapy and in combination with pembrolizumab as a treatment option for patients with solid tumors that display high MSI or deficient mismatch repair (dMMR) including but not limited to colorectal, endometrial, ovarian and gastric cancers. Treatment options for these patients today are limited, and a majority will relapse or become refractory to immune checkpoint inhibitors.

）正在评估VVD-214作为单一疗法以及与派姆单抗联合使用，用于治疗具有高微卫星不稳定性（MSI）或错配修复缺陷（dMMR）的实体瘤患者，包括但不限于结直肠癌、子宫内膜癌、卵巢癌和胃癌。这些患者目前的治疗选择有限，大多数患者会复发或对免疫检查点抑制剂产生耐药性。

The initial data, recently presented at AACR by Timothy Yap, M.B.B.S., Ph.D., clinical investigator and professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, showed early signals of efficacy for VVD-214 in a range of solid tumor types with high MSI. .

德克萨斯大学MD安德森癌症中心的临床研究者、实验性癌症治疗学教授Timothy Yap医学博士最近在AACR上展示的初步数据显示，VVD-214在多种高MSI实体瘤类型中显示出早期的有效性信号。

“VVD-214 is showing promising potential to improve treatment options for patients suffering from MSI-high cancers, a population with high unmet medical need,” said Christian Rommel, Ph.D., Global Head of Research and Development at Bayer’s Pharmaceuticals Division. “It underscores the ability of Vividion’s chemoproteomics technology to identify and advance new treatment opportunities for challenging and intractable diseases, and will be a valuable addition to the company’s portfolio.”.

“VVD-214在改善MSI高癌症患者的治疗选择方面展现了良好的潜力，这是一个存在高度未满足医疗需求的群体，”拜耳制药部门全球研发主管Christian Rommel博士说道。“这凸显了Vividion化学蛋白质组学技术在识别和推进针对棘手且难治性疾病的新治疗机会方面的能力，并将成为公司产品组合中的宝贵补充。”

Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors, an oral STAT3 inhibitor in solid and hematologic malignancies, and an oral RAS-PI3Kα inhibitor in advanced solid tumors. The company is advancing multiple innovative drug discovery programs toward the clinic and has a growing pipeline of opportunities emerging in early discovery in the fields of oncology and immunology leveraging its chemoproteomics platform..

Vividion 还有正在进行的 I 期临床试验，评估一种口服 KEAP1 激活剂在实体瘤中的效果、一种口服 STAT3 抑制剂在实体瘤和血液恶性肿瘤中的效果，以及一种口服 RAS-PI3Kα 抑制剂在晚期实体瘤中的效果。该公司正在推进多个创新药物发现项目进入临床阶段，并利用其化学蛋白质组学平台，在肿瘤学和免疫学领域不断涌现出越来越多的早期发现机会。

About Vividion

关于Vividion

Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics, Inc. 是拜耳集团全资拥有并独立运营的子公司，是一家临床阶段的生物制药公司，利用新型发现技术解锁与疾病密切相关的难以成药的靶点，并开发针对致命癌症和免疫疾病的精准小分子疗法。

The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets.

该公司平台使其能够在广泛涉及多种疾病的已验证蛋白靶点上识别出数百个此前未知的功能口袋，同时从其专有的共价化学库中筛选出与这些口袋以高度选择性方式相互作用的化合物。

The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high-value, traditionally undruggable targets in oncology and immunology. For more information, please visit .

公司正在利用其专有的化学蛋白质组学平台，推进一条多样化的高选择性小分子治疗药物管线，针对肿瘤学和免疫学领域高价值且传统上无法成药的靶点。欲了解更多信息，请访问。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域具有核心竞争力的全球性企业。秉承“人人健康，无饥饿”的使命，公司通过支持应对不断增长和老龄化的全球人口所带来的重大挑战，设计其产品和服务以帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于推动可持续发展，并通过其业务产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表着信任、可靠性和质量。在2024财年，该集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用达62亿欧元。欲了解更多信息，请访问 。